Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALC033
MIFTS: 58

Alcohol Use Disorder

Categories: Genetic diseases, Mental diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Alcohol Use Disorder

About this section

MalaCards integrated aliases for Alcohol Use Disorder:

Name: Alcohol Use Disorder 12 25 42 15
Alcohol Abuse 12 54 15
Alcoholism 25 43
Alcohol Dependence 25
Alcohol Addiction 25
Ethanol Abuse 12

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1574
ICD9CM 34 305.0 305.00
MeSH 43 D000437
NCIt 49 C20701
SNOMED-CT 67 15167005
ICD10 32 F10.1 Z72.1
UMLS 71 C0085762
Sources

Summaries for Alcohol Use Disorder

About this section
MedlinePlus : 42 What is alcohol use disorder (AUD)? For most adults, moderate alcohol use is probably not harmful. However, about 18 million adult Americans have an alcohol use disorder (AUD). This means that their drinking causes distress and harm. AUD can range from mild to severe, depending on the symptoms. Severe AUD is sometimes called alcoholism or alcohol dependence. AUD is a disease that causes Craving - a strong need to drink Loss of control - not being able to stop drinking once you've started Negative emotional state - feeling anxious and irritable when you are not drinking What is binge drinking? Binge drinking is drinking so much at once that your blood alcohol concentration (BAC) level is 0.08% or more. For a man, this usually happens after having 5 or more drinks within a few hours. For a woman, it is after about 4 or more drinks within a few hours. Not everyone who binge drinks has an AUD, but they are at higher risk for getting one. What are the dangers of too much alcohol? Too much alcohol is dangerous. Heavy drinking can increase the risk of certain cancers. It may lead to liver diseases, such as fatty liver disease and cirrhosis. It can also cause damage to the brain and other organs. Drinking during pregnancy can harm your baby. Alcohol also increases the risk of death from car crashes, injuries, homicide, and suicide. How do I know if I have an alcohol use disorder (AUD)? You may have an AUD if you can answer yes to two or more of these questions: In the past year, have you Ended up drinking more or for a longer time than you had planned to? Wanted to cut down or stop drinking, or tried to, but couldn't? Spent a lot of your time drinking or recovering from drinking? Felt a strong need to drink? Found that drinking - or being sick from drinking - often interfered with your family life, job, or school? Kept drinking even though it was causing trouble with your family or friends? Given up or cut back on activities that you enjoyed just so you could drink? Gotten into dangerous situations while drinking or after drinking? Some examples are driving drunk and having unsafe sex. Kept drinking even though it was making you feel depressed or anxious? Or when it was adding to another health problem? Had to drink more and more to feel the effects of the alcohol? Had withdrawal symptoms when the alcohol was wearing off? They include trouble sleeping, shakiness, irritability, anxiety, depression, restlessness, nausea, and sweating. In severe cases, you could have a fever, seizures, or hallucinations. If you have any of these symptoms, your drinking may already be a cause for concern. The more symptoms you have, the more serious the problem is. What should I do if I think that I might have an alcohol use disorder (AUD)? If you think you might have an AUD, see your health care provider for an evaluation. Your provider can help make a treatment plan, prescribe medicines, and if needed, give you treatment referrals. NIH: National Institute on Alcohol Abuse and Alcoholism

MalaCards based summary : Alcohol Use Disorder, also known as alcohol abuse, is related to non-alcoholic steatohepatitis and restless legs syndrome. An important gene associated with Alcohol Use Disorder is ALDH2 (Aldehyde Dehydrogenase 2 Family Member), and among its related pathways/superpathways are Peptide ligand-binding receptors and CREB Pathway. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A substance abuse that involves the recurring use of alcoholic beverages despite negative consequences.

Genetics Home Reference : 25 Alcohol use disorder is a diagnosis made when an individual has severe problems related to drinking alcohol. Alcohol use disorder can cause major health, social, and economic problems, and can endanger affected individuals and others through behaviors prompted by impaired decision-making and lowered inhibitions, such as aggression, unprotected sex, or driving while intoxicated. Alcohol use disorder is a broad diagnosis that encompasses several commonly used terms describing problems with drinking. It includes alcoholism, also called alcohol addiction, which is a long-lasting (chronic) condition characterized by a powerful, compulsive urge to drink alcohol and the inability to stop drinking after starting. In addition to alcoholism, alcohol use disorder includes alcohol abuse, which involves problem drinking without addiction. Habitual excessive use of alcohol changes the chemistry of the brain and leads to tolerance, which means that over time the amount of alcohol ingested needs to be increased to achieve the same effect. Long-term excessive use of alcohol may also produce dependence, which means that when people stop drinking, they have physical and psychological symptoms of withdrawal, such as sleep problems, irritability, jumpiness, shakiness, restlessness, headache, nausea, sweating, anxiety, and depression. In severe cases, agitation, fever, seizures, and hallucinations can occur; this pattern of severe withdrawal symptoms is called delirium tremens. The heavy drinking that often occurs in alcohol use disorder, and can also occur in short-term episodes called binge drinking, can lead to a life-threatening overdose known as alcohol poisoning. Alcohol poisoning occurs when a large quantity of alcohol consumed over a short time causes problems with breathing, heart rate, body temperature, and the gag reflex. Signs and symptoms can include vomiting, choking, confusion, slow or irregular breathing, pale or blue-tinged skin, seizures, a low body temperature, a toxic buildup of substances called ketones in the blood (alcoholic ketoacidosis), and passing out (unconsciousness). Coma, brain damage, and death can occur if alcohol poisoning is not treated immediately. Chronic heavy alcohol use can also cause long-term problems affecting many organs and systems of the body. These health problems include irreversible liver disease (cirrhosis), inflammation of the pancreas (pancreatitis), brain dysfunction (encephalopathy), nerve damage (neuropathy), high blood pressure (hypertension), stroke, weakening of the heart muscle (cardiomyopathy), irregular heartbeats (arrhythmia), and immune system problems. Long-term overuse of alcohol also increases the risk of certain cancers, including cancers of the mouth, throat, esophagus, liver, and breast. Alcohol use in pregnant women can cause birth defects and fetal alcohol syndrome, which can lead to lifelong physical and behavioral problems in the affected child.

Wikipedia : 74 Alcoholism, also known as alcohol use disorder (AUD), is a broad term for any drinking of alcohol that... more...

Sources

Related Diseases for Alcohol Use Disorder

About this section

Diseases in the Alcohol Use Disorder family:

Alcohol Sensitivity, Acute

Diseases related to Alcohol Use Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2203)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic steatohepatitis 34.7 GPT GGT1
2 restless legs syndrome 32.6 SLC6A4 HTR3A DRD3 DRD2 DRD1 ADH1B
3 methanol poisoning 32.1 CYP2E1 ALDH2 ADH1C ADH1B
4 depression 31.9 SLC6A4 HTR2A HTR1A BDNF
5 conduct disorder 31.5 SLC6A4 GABRA2 DRD2 ALDH2
6 avoidant personality disorder 31.4 SLC6A4 HTR1B DRD3 DRD2
7 post-traumatic stress disorder 31.4 SLC6A4 HTR2A DRD2 BDNF
8 withdrawal disorder 31.4 GRIN2B DRD2 DRD1
9 mental depression 31.4 SLC6A4 HTR3A HTR2A HTR1B HTR1A GRIN2B
10 anxiety 31.2 SLC6A4 HTR3A HTR2A HTR1B HTR1A GRIN2B
11 personality disorder 31.2 SLC6A4 HTR3A HTR2A HTR1B HTR1A DRD3
12 generalized anxiety disorder 31.1 SLC6A4 HTR3A HTR2A HTR1A DRD2 BDNF
13 mood disorder 31.1 SLC6A4 HTR3A HTR2A HTR1B HTR1A DRD3
14 dysthymic disorder 31.1 SLC6A4 HTR2A HTR1A BDNF
15 social phobia 31.1 SLC6A4 HTR3A HTR1A DRD2
16 alexithymia 31.1 SLC6A4 HTR1A DRD2 ANKK1
17 antisocial personality disorder 31.1 SLC6A4 HTR2A HTR1B GABRA2 DRD2 ANKK1
18 major depressive disorder 31.1 SLC6A4 HTR3A HTR2A HTR1B HTR1A GRM5
19 agoraphobia 31.0 SLC6A4 HTR2A HTR1A
20 eating disorder 31.0 SLC6A4 HTR2A DRD3 DRD2 BDNF ANKK1
21 cocaine abuse 31.0 SLC6A4 HTR3A DRD3 DRD2 DRD1 BDNF
22 sexual disorder 31.0 SLC6A4 HTR3A HTR2A HTR1A DRD2
23 borderline personality disorder 31.0 SLC6A4 HTR3A HTR2A HTR1B HTR1A DRD2
24 opiate dependence 31.0 SLC6A4 DRD3 DRD2 DRD1 ANKK1
25 premenstrual tension 31.0 HTR1A ANKK1
26 amnestic disorder 30.9 HTR3A HTR1A GRIN2B DRD2 BDNF
27 tic disorder 30.9 SLC6A4 HTR2A DRD3 DRD2 DRD1
28 phobic disorder 30.9 SLC6A4 HTR2A HTR1A BDNF
29 cannabis abuse 30.9 HTR1A GABRA2 DRD2 BDNF
30 bulimia nervosa 30.9 SLC6A4 HTR3A HTR2A HTR1B DRD2 BDNF
31 liver cirrhosis 30.9 GPT GGT1 CYP2E1 ALDH2 ADH1C ADH1B
32 retrograde amnesia 30.9 SLC6A4 HTR1A GRIN2B BDNF
33 substance abuse 30.9 SLC6A4 HTR2A HTR1B HTR1A GPT GABRA2
34 anorexia nervosa 30.8 SLC6A4 HTR2A HTR1A BDNF
35 fetal alcohol syndrome 30.8 GRIN2B CYP2E1 BDNF ALDH2 ADH1C ADH1B
36 sleep disorder 30.8 SLC6A4 HTR2A HTR1A DRD2 BDNF
37 panic disorder 30.8 SLC6A4 HTR3A HTR2A HTR1B HTR1A DRD3
38 pathological gambling 30.8 SLC6A4 HTR2A DRD3 DRD2 DRD1 ANKK1
39 schizoaffective disorder 30.8 SLC6A4 HTR2A HTR1A DRD3 DRD2 BDNF
40 bipolar i disorder 30.8 SLC6A4 HTR2A HTR1A GRIN2B DRD3 DRD2
41 endogenous depression 30.8 SLC6A4 HTR3A HTR2A HTR1A BDNF
42 alcohol-related birth defect 30.8 ADH1C ADH1B
43 alcohol dependence 30.7 SLC6A4 HTR3A HTR2A HTR1B HTR1A GRM5
44 paranoid schizophrenia 30.7 SLC6A4 HTR2A HTR1A BDNF
45 attention deficit-hyperactivity disorder 30.7 SLC6A4 HTR2A HTR1B HTR1A GRM5 GRIN2B
46 autism spectrum disorder 30.7 SLC6A4 HTR2A HTR1B GRIN2B DRD3 DRD2
47 traumatic brain injury 30.7 DRD2 BDNF
48 postpartum depression 30.7 SLC6A4 HTR1A BDNF
49 hypertension, essential 30.7 SLC6A4 HTR2A GPT GGT1 DRD3 DRD2
50 diabetes mellitus, noninsulin-dependent 30.7 HTR2A GPT GGT1 DRD2 CYP2E1 BDNF

Graphical network of the top 20 diseases related to Alcohol Use Disorder:



Diseases related to Alcohol Use Disorder
Sources

Symptoms & Phenotypes for Alcohol Use Disorder

About this section

GenomeRNAi Phenotypes related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Alcohol Use Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 ALDH2 BDNF CYP2E1 DRD1 DRD2 DRD3
2 growth/size/body region MP:0005378 10.17 ADH1C ALDH2 BDNF CYP2E1 DRD1 DRD2
3 homeostasis/metabolism MP:0005376 10.1 ADH1C ALDH2 BDNF CYP2E1 DRD1 DRD2
4 endocrine/exocrine gland MP:0005379 10.02 ALDH2 BDNF DRD2 GGT1 GRM5 HTR1B
5 integument MP:0010771 9.85 ALDH2 BDNF DRD1 DRD2 GABBR1 GABRA2
6 mortality/aging MP:0010768 9.83 ADH1C ALDH2 BDNF CYP2E1 DRD1 DRD2
7 nervous system MP:0003631 9.4 ALDH2 BDNF DRD1 DRD2 DRD3 GABBR1
Sources

Drugs & Therapeutics for Alcohol Use Disorder

About this section

Drugs for Alcohol Use Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 616)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
4
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
5
Zinc Approved, Investigational Phase 4 7440-66-6 32051
6
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
7
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
8
Nefopam Approved, Investigational Phase 4 13669-70-0
9
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
10
Amisulpride Approved, Investigational Phase 4 71675-85-9, 53583-79-2 2159
11
Insulin glargine Approved Phase 4 160337-95-1
12
Insulin lispro Approved Phase 4 133107-64-9
13
Losartan Approved Phase 4 114798-26-4 3961
14
Amlodipine Approved Phase 4 88150-42-9 2162
15
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
16
Atenolol Approved Phase 4 29122-68-7 2249
17
Pravastatin Approved Phase 4 81093-37-0 54687
18
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
19
Lenograstim Approved, Investigational Phase 4 135968-09-1
20
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
21
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
22
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
23
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
24
Baclofen Approved Phase 4 1134-47-0 2284
25
Norepinephrine Approved Phase 4 51-41-2 439260
26
Levetiracetam Approved Phase 4 102767-28-2 441341
27
Memantine Approved, Investigational Phase 4 19982-08-2 4054
28
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
29
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
30
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
31
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
32
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
33
Cycloserine Approved Phase 4 68-41-7 401 6234
34
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
35
Oxazepam Approved Phase 4 604-75-1 4616
36
Sodium oxybate Approved Phase 4 502-85-2 5360545
37
Chlorzoxazone Approved Phase 4 95-25-0 2733
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
39
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
40
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
41
Methadone Approved Phase 4 76-99-3 4095
42
Ribavirin Approved Phase 4 36791-04-5 37542
43
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
44
Haloperidol Approved Phase 4 52-86-8 3559
45
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
46
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
47
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
48
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
49
Simvastatin Approved Phase 4 79902-63-9 54454
50
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516

Interventional clinical trials:

(show top 50) (show all 1601)
# Name Status NCT ID Phase Drugs
1 The Role of Pharmacotherapy in Prevention of Relapse in Alcohol Dependence Unknown status NCT00120601 Phase 4 Naltrexone;Acamprosate
2 Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Open-Label Study Unknown status NCT01135602 Phase 4 Topiramate
3 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
4 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
5 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
6 The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
7 Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids Unknown status NCT01967433 Phase 4 Diphenhydramine;Placebo
8 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
9 Antabuse in Severe Alcoholism: an Open Controlled Study Unknown status NCT00431262 Phase 4 antabuse (disulfiram)
10 Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users Unknown status NCT02945293 Phase 4
11 Effect of a Treatment Switch From Protease Inhibitor to Raltegravir-based ART on Myeloid Cell Inflammation in HIV-infected Patients. Unknown status NCT02691065 Phase 4 Integrase Inhibitor
12 Clinical Trial: Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and GERD-related Sleep Disturbances in Patients With Erosive GERD Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
13 A MULTICENTER, RANDOMIZED, CONTROLLED STUDY OF EPIDURAL ANALGESIA FOR SEVERE ACUTE PANCREATITIS Unknown status NCT02126332 Phase 4
14 Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging Unknown status NCT02095938 Phase 4 amisulpride
15 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
16 the Safety and Effect in TB Patients With NAC Unknown status NCT02889757 Phase 4 Acteylcysteine
17 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
18 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
19 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Unknown status NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine
20 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
21 Recovery of Muscle Function After Deep Neuromuscular Block by Means of Dia-phragm Ultrasonography and Adductor Pollicis Acceleromyography: Comparison of Neostigmine vs. Sugammadex as Reversal Drugs. Unknown status NCT02698969 Phase 4 Sugammadex;Neostigmine;Atropine;Rocuronium;Fentanyl;Propofol;Sevoflurane
22 A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence Completed NCT00452543 Phase 4 acamprosate;escitalopram;Placebo
23 Citicoline for Alcohol Dependence Completed NCT02074735 Phase 4 Placebo;Citicoline
24 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
25 Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial Completed NCT00190957 Phase 4 Atomoxetine;placebo
26 Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI): A Pilot Study Completed NCT00453804 Phase 4 injectable naltrexone;oral naltrexone
27 The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
28 A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD Completed NCT01749215 Phase 4 Topiramate;placebo
29 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
30 Non-Response to Naltrexone (NTX): Next Steps in Managing Alcoholism Completed NCT00115037 Phase 4 Naltrexone;placebo
31 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
32 Naltrexone Treatment of Alcohol Abuse in Schizophrenia Completed NCT00145847 Phase 4 Naltrexone or Placebo
33 Timing of Smoking Intervention in Alcohol Treatment Completed NCT00000444 Phase 4 nicotine replacement patch
34 Extended-release Naltrexone (Vivitrol) for the Treatment of Alcohol Dependence in Urban Primary Care: a Feasibility Study Completed NCT00620750 Phase 4 Extended release injectable naltrexone (Vivitrol)
35 SSRI Treatment of Dual Diagnosis PTSD and Alcohol Dependence: A Test of the Serotonergic Hypothesis Completed NCT02504931 Phase 4 Sertraline;Placebo
36 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
37 Combined Pharmacotherapy in Depressed Alcoholics Completed NCT00006204 Phase 4 naltrexone (Revia);fluoxetine (Prozac)
38 The Treatment of Late Life Major Depression Complication by Alcohol Completed NCT00018824 Phase 4 NALTREXONE;Placebo
39 Naltrexone Treatment of Alcohol Dependence Completed NCT00000452 Phase 4 naltrexone (Revia)
40 Oral Naltrexone for Improved Medication Compliance Among HIV-infected Men With Alcohol Use Disorder Completed NCT01377168 Phase 4 oral naltrexone;Placebo pill
41 A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence Completed NCT01015586 Phase 4 Lamotrigine;Placebo
42 Exploratory, Interventional, Open-label, Fixed-dose Study With Selincro® As-needed Use, in Alcohol Dependent Patients With Liver Impairment Completed NCT02197598 Phase 4 nalmefene
43 Zonisamide vs. Placebo in the Treatment of Alcohol Dependence Completed NCT00595556 Phase 4 zonisamide;Placebo
44 Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder Completed NCT00006489 Phase 4 Naltrexone;Placebo
45 Etiology and Treatment of Alcohol Dependence Completed NCT00000442 Phase 4 naltrexone (Revia)
46 Bupropion as a Smoking Cessation Aid in Alcoholics Completed NCT00044434 Phase 4 bupropion (Wellbutrin)
47 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
48 Disulfiram Combined With Lorazepam for Treatment of Patients With Alcohol Dependence and Primary or Secondary Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
49 Targeted Naltrexone for Early Problem Drinkers Completed NCT00000455 Phase 4 naltrexone
50 Nalmefene in Nicotine and Alcohol Dependence Completed NCT00000437 Phase 4 Naltrexone Tablet and Nicotine Patch;Naltrexone Tablet and Placebo Patch;Placebo Tablet and Nicotine Patch;Placebo Tablet and Placebo Patch

Search NIH Clinical Center for Alcohol Use Disorder

Cochrane evidence based reviews: alcoholism

Sources

Genetic Tests for Alcohol Use Disorder

About this section
Sources

Anatomical Context for Alcohol Use Disorder

About this section

MalaCards organs/tissues related to Alcohol Use Disorder:

40
Liver, Brain, Testes, Heart, Bone, Lung, Pancreas
Sources

Publications for Alcohol Use Disorder

About this section

Articles related to Alcohol Use Disorder:

(show top 50) (show all 18235)
# Title Authors PMID Year
1
Endocannabinoid System and Alcohol Abuse Disorders. 61 42
31332736 2019
2
Mike's Labels. 42
31412177 2019
3
Alcohol use disorders. 42
31478502 2019
4
A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. 54 61
20153935 2010
5
The opioid systems--panacea and nemesis. 54 61
20494127 2010
6
Validation of a headspace solid-phase microextraction-GC-MS/MS for the determination of ethyl glucuronide in hair according to forensic guidelines. 54 61
20061100 2010
7
Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - a narrative review. 54 61
19943812 2010
8
Brief motivational interviewing for DWI recidivists who abuse alcohol and are not participating in DWI intervention: a randomized controlled trial. 54 61
19930236 2010
9
RNA interference against aldehyde dehydrogenase-2: development of tools for alcohol research. 54 61
19251111 2009
10
[Association of the functional serotonin transporter promoter polymorphism (5-HTTLPR) with externalizing and internalizing aggressivity and alcohol abuse]. 54 61
19331786 2008
11
[Acute and chronic alcohol abuse and work]. 54 61
19288791 2008
12
Effectiveness of the CAGE questionnaire, gamma-glutamyltransferase and mean corpuscular volume of red blood cells as markers for alcohol-related problems in the workplace. 54 61
18337017 2008
13
The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. 54 61
18061976 2008
14
[The concentration of sialylated glycoproteins in the sera of alcohol dependent men]. 54 61
18293845 2007
15
Development and multicenter evaluation of the N latex CDT direct immunonephelometric assay for serum carbohydrate-deficient transferrin. 54 61
17412797 2007
16
Biomarkers in alcoholism. 54 61
17045579 2007
17
Ethnicity and gamma-glutamyltransferase in men and women with alcohol use disorders. 54 61
17098749 2007
18
Obesity and the clinical use of serum GGT activity as a marker of heavy drinking. 54 61
17763184 2007
19
Genetic and environmental influences on the development of alcoholism: resilience vs. risk. 54 61
17347351 2006
20
Argininosuccinate lyase deficiency (ASL) and carbohydrate-deficient transferrin (CDT): experience with four independent CDT analysis methods--misleading results given by the %CDT TIA assay. 54 61
16808909 2006
21
[Alcohol abuse as a risk factor for ARDS]. 54 61
17176845 2006
22
Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. 54 61
16945079 2006
23
[New and traditional laboratory markers of alcohol abuse in hospitalized alcohol dependent men]. 54 61
17037822 2006
24
Association of galanin haplotypes with alcoholism and anxiety in two ethnically distinct populations. 54 61
16314872 2006
25
[Depression of serum esterase and lipoprotein lipase activities in acute and longitudinal actions of ethanol]. 54 61
16739925 2006
26
gamma-Glutamyltransferase is a promising biomarker for cardiovascular risk. 54 61
16891060 2006
27
[New methods for the determination of transferrin isoforms in the diagnostics of alcohol abuse]. 54 61
16489296 2006
28
Differential susceptibility of transferrin glycoforms to chymotrypsin: a proteomics approach to the detection of carbohydrate-deficient transferrin. 54 61
16331960 2005
29
Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. 54 61
16385229 2005
30
Cytochrome P450 2E1 high activity polymorphism in alcohol abuse and end-organ disease. 54 61
16425414 2005
31
Use of laboratory markers and the audit questionnaire by primary care physicians to detect alcohol abuse by patients. 54 61
16215269 2005
32
Disturbances of electrolytes and blood chemistry in acute alcohol intoxication. 54 61
15773422 2005
33
[Assessment of the usefulness of combination of selected clinical and demographic parameters in prediction of the severity of liver fibrosis in patients with chronic hepatitis C]. 54 61
16190546 2005
34
Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B. 54 61
15772792 2005
35
Serum sialic acid and gamma-glutamyltransferase levels in alcohol-dependent individuals. 54 61
15639592 2004
36
Multicenter validation study of the %CDT TIA kit in alcohol abuse and alcohol dependence. 54 61
15365303 2004
37
[Iron overload disease: recent findings]. 54 61
15529941 2004
38
Genetic polymorphism in ethanol metabolism: acetaldehyde contribution to alcohol abuse and alcoholism. 54 61
15164086 2004
39
Clinical features and risk factors of patients with fatty liver in Guangzhou area. 54 61
15040041 2004
40
Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. 54 61
15084894 2004
41
Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. 54 61
15288384 2004
42
Polymorphisms of the dopamine D2 receptor, serotonin transporter, and GABA(A) receptor beta(3) subunit genes and alcoholism in Mexican-Americans. 54 61
15066703 2004
43
[Study on the relationship between smoking, alcohol intake and hyperlipidemia in fishermen]. 54 61
14761628 2003
44
Use of biomarkers for alcohol use disorders in clinical practice. 54 61
14984245 2003
45
Anxiety and alcohol abuse disorders: a common role for CREB and its target, the neuropeptide Y gene. 54 61
12967770 2003
46
Transcription profiling reveals mitochondrial, ubiquitin and signaling systems abnormalities in postmortem brains from subjects with a history of alcohol abuse or dependence. 54 61
12774316 2003
47
Recognition of alcohol and substance abuse. 54 61
12722853 2003
48
The effects of ethanol on the glycosylation of human transferrin. 54 61
12626412 2003
49
Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. 54 61
12737448 2003
50
Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. 54 61
11704927 2001
Sources

Variations for Alcohol Use Disorder

About this section
Sources

Expression for Alcohol Use Disorder

About this section
Search GEO for disease gene expression data for Alcohol Use Disorder.
Sources

Pathways for Alcohol Use Disorder

About this section

Pathways related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 65
Show member pathways
 13.48 HTR2A HTR1B HTR1A GRM5 GRIN2B GABRA2
2
CREB Pathway 63
Show member pathways
 13.21 HTR3A HTR2A HTR1B HTR1A GRM5 GRIN2B
3
Transmission across Chemical Synapses 65
Show member pathways
 12.9 SLC6A4 GRM5 GRIN2B GABRA2 GABBR1 ALDH2
4
Circadian entrainment 36
Show member pathways
 12.66 GRM5 GRIN2B DRD3 DRD2 DRD1
5
Dopamine-DARPP32 Feedback onto cAMP Pathway 63
12.26 GRIN2B DRD3 DRD2 DRD1
7
Long-term potentiation 36
Show member pathways
 12.08 GRM5 GRIN2B DRD2 DRD1
8
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.04 SLC6A4 HTR3A HTR2A HTR1A BDNF
9
cAMP signaling pathway 36
12.03 HTR1B HTR1A GRIN2B GABBR1 DRD2 DRD1
10
Amphetamine addiction 36
Show member pathways
 11.92 GRIN2B DRD2 DRD1 BDNF
11
Taste transduction 36
Show member pathways
 11.89 HTR3A HTR1B HTR1A GRM5 GABRA2 GABBR1
12
Serotonergic synapse 36
11.83 SLC6A4 HTR3A HTR2A HTR1B HTR1A
13
Monoamine GPCRs 1
Show member pathways
 11.78 HTR2A HTR1B HTR1A DRD3 DRD2 DRD1
14
Gap junction 36
11.76 HTR2A GRM5 DRD2 DRD1
15
Microglia Activation During Neuroinflammation: Steady-State Microglia 64
11.36 GABBR1 DRD2 DRD1 BDNF
16
Cyclophosphamide Pathway, Pharmacodynamics 60
Show member pathways
 11.2 ALDH2 ADH1C ADH1B
17
DARPP-32 Phosphorylation 64
11.04 DRD3 DRD2 DRD1
18
Synaptic Neurotransmission Pathways: GABAergic Inhibition 64
10.88 GRM5 GABRA2 GABBR1
19
GPCRs, Class C Metabotropic glutamate, pheromone 1
10.83 GRM5 GABBR1
20
ethanol degradation II 1
Show member pathways
 10.81 CYP2E1 ALDH2 ADH1B
21
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
10.8 SLC6A4 HTR3A HTR2A HTR1B HTR1A
22
noradrenaline and adrenaline degradation 1
Show member pathways
 10.79 ALDH2 ADH1B
23
Abacavir Pathway, Pharmacokinetics/Pharmacodynamics 60
10.73 ADH1C ADH1B
24
acetone degradation I (to methylglyoxal) 1
Show member pathways
 10.65 CYP2E1 ADH1B
25
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.46 SLC6A4 HTR1B HTR1A DRD3 DRD2 DRD1
Sources

GO Terms for Alcohol Use Disorder

About this section

Cellular components related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.34 SLC6A4 HTR3A HTR2A HTR1B HTR1A GRM5
2 plasma membrane GO:0005886 10.24 SLC6A4 HTR3A HTR2A HTR1B HTR1A GRM5
3 synapse GO:0045202 9.97 SLC6A4 HTR3A HTR1A GRIN2B GABRA2 GABBR1
4 neuron projection GO:0043005 9.88 SLC6A4 HTR3A GRM5 GRIN2B GABRA2
5 dendrite GO:0030425 9.86 HTR2A HTR1B HTR1A GABRA2 GABBR1 DRD2
6 axon GO:0030424 9.85 HTR3A HTR2A GABRA2 DRD2 BDNF
7 glutamatergic synapse GO:0098978 9.83 HTR3A HTR2A DRD3 DRD2 DRD1
8 postsynaptic membrane GO:0045211 9.81 HTR3A GRIN2B GABRA2 GABBR1
9 integral component of plasma membrane GO:0005887 9.73 SLC6A4 HTR3A HTR2A HTR1B HTR1A GRM5
10 GABA-ergic synapse GO:0098982 9.72 GABRA2 GABBR1 DRD3 DRD2 DRD1
11 integral component of postsynaptic membrane GO:0099055 9.55 SLC6A4 HTR3A HTR2A DRD2 DRD1
12 dopaminergic synapse GO:0098691 9.54 DRD3 DRD2
13 serotonergic synapse GO:0099154 9.4 SLC6A4 HTR1B
14 integral component of presynaptic membrane GO:0099056 9.1 SLC6A4 HTR3A HTR2A HTR1B DRD2 DRD1

Biological processes related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.23 HTR2A HTR1B HTR1A GRM5 GABBR1 DRD3
2 signal transduction GO:0007165 10.22 HTR3A HTR2A HTR1B HTR1A GRM5 GABRA2
3 locomotory behavior GO:0007626 9.93 GRM5 DRD3 DRD2 DRD1
4 memory GO:0007613 9.91 SLC6A4 HTR2A DRD1 BDNF
5 response to drug GO:0042493 9.91 SLC6A4 HTR2A HTR1B DRD3 DRD2 DRD1
6 response to toxic substance GO:0009636 9.9 SLC6A4 DRD3 DRD2
7 modulation of chemical synaptic transmission GO:0050804 9.89 GRIN2B DRD2 BDNF
8 learning GO:0007612 9.87 GRM5 DRD3 DRD1
9 excitatory postsynaptic potential GO:0060079 9.87 HTR3A GRIN2B DRD2
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.87 HTR2A HTR1B HTR1A DRD1
11 synapse assembly GO:0007416 9.86 DRD2 DRD1 BDNF
12 learning or memory GO:0007611 9.86 GRM5 GRIN2B DRD3
13 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.86 DRD3 DRD2 DRD1
14 visual learning GO:0008542 9.85 DRD3 DRD2 DRD1
15 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.84 DRD3 DRD2 DRD1
16 response to amphetamine GO:0001975 9.83 DRD3 DRD2 DRD1
17 regulation of postsynaptic membrane potential GO:0060078 9.83 HTR3A GRM5 GABRA2 GABBR1
18 feeding behavior GO:0007631 9.82 HTR1B DRD2 DRD1
19 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.81 HTR2A HTR1B HTR1A
20 regulation of synaptic vesicle exocytosis GO:2000300 9.81 HTR2A HTR1B DRD2 DRD1
21 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.8 DRD3 DRD2 DRD1
22 chemical synaptic transmission GO:0007268 9.8 HTR3A HTR2A HTR1B HTR1A GRM5 GRIN2B
23 temperature homeostasis GO:0001659 9.79 HTR2A DRD2 DRD1
24 dopamine receptor signaling pathway GO:0007212 9.78 DRD3 DRD2 DRD1
25 synaptic transmission, dopaminergic GO:0001963 9.77 DRD3 DRD2 DRD1
26 vasoconstriction GO:0042310 9.77 SLC6A4 HTR1B HTR1A
27 prepulse inhibition GO:0060134 9.76 DRD3 DRD2 DRD1
28 dopamine metabolic process GO:0042417 9.75 DRD3 DRD2 DRD1
29 negative regulation of voltage-gated calcium channel activity GO:1901386 9.73 DRD3 DRD2
30 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.73 DRD3 DRD2 DRD1
31 regulation of dopamine secretion GO:0014059 9.73 HTR2A HTR1B DRD3 DRD2
32 behavioral response to ethanol GO:0048149 9.72 DRD3 DRD2
33 positive regulation of renal sodium excretion GO:0035815 9.72 DRD3 DRD2
34 grooming behavior GO:0007625 9.72 DRD2 DRD1
35 striatum development GO:0021756 9.72 DRD2 DRD1
36 G protein-coupled receptor internalization GO:0002031 9.72 HTR1B DRD3 DRD2
37 regulation of potassium ion transport GO:0043266 9.71 DRD3 DRD2
38 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.71 DRD3 DRD1
39 regulation of behavior GO:0050795 9.71 HTR1B HTR1A
40 regulation of dopamine metabolic process GO:0042053 9.71 HTR1A DRD1
41 ethanol oxidation GO:0006069 9.71 ALDH2 ADH1C ADH1B
42 peristalsis GO:0030432 9.7 DRD2 DRD1
43 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.7 DRD3 DRD2
44 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.7 GRM5 DRD2
45 drinking behavior GO:0042756 9.69 HTR1B DRD2
46 cerebral cortex GABAergic interneuron migration GO:0021853 9.68 DRD2 DRD1
47 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.67 HTR1B HTR1A
48 negative regulation of dopamine receptor signaling pathway GO:0060160 9.67 DRD3 DRD2
49 regulation of neurotransmitter uptake GO:0051580 9.67 DRD3 DRD2
50 behavior GO:0007610 9.67 HTR2A HTR1B HTR1A

Molecular functions related to Alcohol Use Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 HTR2A HTR1B HTR1A GRM5 DRD3 DRD2
2 neurotransmitter receptor activity GO:0030594 9.61 HTR2A HTR1B HTR1A
3 G protein-coupled serotonin receptor activity GO:0004993 9.58 HTR2A HTR1B HTR1A
4 drug binding GO:0008144 9.56 HTR2A HTR1B DRD3